A case for screening real-world data for collateral drug benefits: Glucagon-like peptide 1 receptor agonists and bile acid diarrhea.

Martin Torp Rahbek Lars Christian Lund Nina Sahlertz Kristiansen

Published in: Pharmacoepidemiology and drug safety (2023)

Using the SSA methodology, we obtained estimates of a collateral drug benefit that were compatible with trial results. These results support the use of epidemiological analyses of observational data as instrument for detecting collateral drug benefits.

Keyphrases

electronic health record
adverse drug
big data
study protocol
drug induced
emergency department
machine learning
phase iii
irritable bowel syndrome
deep learning